期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

左西孟旦的作用机制及临床应用研究进展 被引量：13

原文传递
导出
摘要 左西孟旦由Orion制药公司开发用于治疗急性失代偿性心衰，具有双重作用机制。它可与一种影响心肌收缩的蛋白——肌钙蛋白c结合，使其对钙离子的敏感性增强，增加心脏收缩力，避免因钙过度蓄积而引起的心律失常；还可通过开放血管平滑肌上的ATP敏感型钾通道引起血管扩张。研究者认为左西盂旦影响心肌收缩和血管舒张作用进而增加心输出量的同时并不增加心肌的耗氧量。
作者 郭辉荣 王东波 徐志勇
机构地区 滨州市人民医院药剂科
出处 《中国基层医药》 CAS 2012年第23期3643-3644,共2页 Chinese Journal of Primary Medicine and Pharmacy
关键词 左西孟旦 临床应用 肌钙蛋白c 心肌收缩 血管舒张作用 ORION 心脏收缩力 血管平滑肌
分类号 R96 [医药卫生—药理学]
  • 相关文献

参考文献14

  • 1Kivikko M, Antila S, Eha J, et al. Pharmacokinetics of levosimen- dan and its metabolites during and after a 24-hour continuous in fusion in patients with severe heart failure. Int J Clin Pharmaeol Ther,2002,40(10) :465-471.
  • 2Gheorghiade M,Teerlink JR, Mebazaa A. Pharmacology of new a- gents for the acute heart failure syndrome. Am J Cardio1,2005,96 (6) :68-73.
  • 3Ng TM. Levosimendan,a new calcium-sensitizing inotrope for heart failure. Pharmacotherapy ,2004,24 ( 10 ) : 1366-1384.
  • 4Mebazaa A, Erhardt L. Levosimendan : a new dual-action drug in the treatment of acute heart failure. Int J Clin Pract, 2003,57 (5) :410-416.
  • 5Cleland JG, Nikitin N, McGowan J. Levosimendan:first in a new class of inodilator for acute and chronic severe heart failure. Ex-pert Rev Cardiovasc Ther,2004,2( 1 ) :9-19.
  • 6Kaheinen P, Pollesello P, Levijoki J. Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart. J Cardiovasc Pharmaco1,2004,43 (4) :555-561.
  • 7Paraskevaidis IA, Parissis LIT, Th Kremastinos D. Anti-inflammato- ry and antiapoptotie effects of levosimendan in decompensated heart failure:a novel mechanism of drug-induced improvement in contractile performance of the failing heart. Curr Med Chem Card- iovase Hematol Agents ,2005,3 ( 3 ) :243-247.
  • 8Michaels AD, McKeown B, Kostal M, et al. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ven- tricular wall stress, and myocardia loxygen uptake. Circulation, 2005,111 (12) : 1504-1509.
  • 9Maytin M, Colucci WS. Cardioprotection:A new paradigm in the management of acute heart failure syndromes. Am J Cardiol, 2005,96 ( Suppl ) : 26 -31.
  • 10Kyrzopoulos S, Adamopoulos S, Parissis JT, et al. Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients. Int J Cardio1,2005,99 (3) :409-413.

二级参考文献20

  • 1Lemos J, McGuire D, Drazner M, et al. B-type natriuretic piptide in cardiovascular disease J. Lancet,2003,362 (14) :316-322.
  • 2Lee SC, Stevens TL, Sandberg SM, et al. The potential of brainna- triuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. J Card Fail, 2002,8(3) :149-154.
  • 3Dec GW. Acute decompensated heart failure:the shrinking role of inotropic therapy. Am Coll Cordial,2005,46( 1 ) :65-67.
  • 4De Luca L, Colucci WS, Nieminen MS, et al. Evidence-based use of levosimendan in different clinical settings. Eur Heart, 2006,27 (16) : 1908-1920.
  • 5Nieminen MS, Cleland JG, Eha J, et al. Oral levosimendan in patients with severe chronic heart failure-the PERSIST study. Eur J Heart Fail, 2008,10 ( 12 ) : 1246 -1254.
  • 6Nieminen M. Levosimendan in Patients with Left Heart Failure After Acute Myocardial Infarction-Review of the RUSSLAN Study and Future Developments with Levosimendan. J Fur Kardiol, 2011,9 ( 3 ) :45-48.
  • 7Dao Q, Krishnaswamy P, Kazanegra R, et al. Utilty of B-rype natriuretic peptide in the diagnosis of congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coil Cardial, 2001,37(2) :379-385.
  • 8Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure ( the LIDO study) : a randomized double-blind trial. Lancet,2002,360 (9328) : 196-202.
  • 9Moiseyev VS, P? der P,Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, Levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study ( RUSSLAN ). Eur Heart J,2002,23 ( 18 ) : 1422-1432.
  • 10Cleland JG, Ghosh J, Freemantel N, et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronization therapy in heart failure. Eur J Heart Fail ,2004,6 (4) :501-508.

共引文献15

同被引文献116

  • 1Mcmurray JJ, Adamopoulos S, Anker SD,et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Di- agnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. De- veloped in collaboration with the Heart Failure Associa- tion (HFA) of the ESC[J]. Eur J Heart Fail,2012,14 (8) :803- 869.
  • 2Rognoni A, Lupi A, Lazzero M, et al. Levosimendan: from basic science to clinical trials[J]. Recent Pat Card- iovasc Drug Discov, 2011,6 ( 1 ) : 9-15.
  • 3McCann P, Hauptman PJ. Inotropic therapy., an im- portant role in the treatment of advanced symptomatic heart failure[J]. Med Clin North Am, 2012,96 (5) . 943-954.
  • 4Ornerovic E, Waagstein F, Swedberg K. Is levosimen- dan better than dobutamine in acute heart failure in pa- tients on beta-blockade treatment? What is the evi dence? [J]. EurJ Heart Fail, 2010,12(4): 313-314.
  • 5Paraskevaidis IA,Parissis JT, Kremastinos D. Anti in- flammatory and anti-apoptotic effects of levosimendan in decompensated heart failure: a novel mechanism of drug-induced improvement in contractile performance of the failing heart[J]. Curr Med Chem Cardiovasc Hema- tol Agents,2005,3(3) : 243-247.
  • 6Gullestad L,Ueland T, Vinge LE, et al. Inflammatory cytokines in heart failure~ mediators and markers[J]. Cardiology, 2012,122(1) : 23-35.
  • 7Palazzuoli A, Gallotta M, Quatrini I, et al. Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure[J]. Vascular health and risk management,2010,6 (1) .411-418.
  • 8努尔兰·阿合西塔依,马丽娜·艾山拜.左西孟旦治疗难治性心力衰竭40例分析.中国社区医师(医学专业),2011,13(28):17-18.
  • 9陆再英;钟南山.内科学[M]北京:人民卫生出版社,2008286.
  • 10Dec GW. Acute decompensated heart failure:the shrinking role of inotropic therapy[J].J Am Coil Cardio1,2005,(1):65-67.

引证文献13

二级引证文献168

中国基层医药
2012年 第23期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部